Aug 2017 $20 M No. 6 $10 to $50 million 16
Apellis Pharmaceuticals, Inc.: Raise no. 6, Aug 2017 × Investors in this round 16 investors had bought by the notice of Aug 17, 2017: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $60 M offered; $40 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cedric Francois · Executive Officer, Director Daniel Sinclair Geffken · Executive Officer David Sinclair Watson · Executive Officer Nicole Sinclair Perry · Executive Officer Pascal Deschatelets · Executive Officer Robert Sinclair Kim · Executive Officer Steven Sinclair Axon · Executive Officer A. Sinclair Dunlop · Director Alec Sinclair Machiels · Director Bihua Sinclair Chen · Director Gerald Sinclair Chan · Director Maha Sinclair Katabi · Director Robert Sinclair Adelman · Director Stephanie Sinclair O'Brien · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Cedric Francois, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 17, 2017. Read the notice at the SEC .
equity SEC Dec 2015 $47 M No. 5 $10 to $50 million 7
Apellis Pharmaceuticals, Inc.: Raise no. 5, Dec 2015 × Investors in this round 7 investors had bought by the notice of Feb 8, 2016: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $47 M of $47 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cedric Francois · Executive Officer, Director Daniel Sinclair Geffken · Executive Officer David Sinclair Watson · Executive Officer Federico Sinclair Grossi · Executive Officer Nicole Sinclair Perry · Executive Officer Pascal Deschatelets · Executive Officer A. Sinclair Dunlop · Director Alec Sinclair Machiels · Director Bihua Sinclair Chen · Director Gerald Sinclair Chan · Director Robert Sinclair Adelman · Director Stephanie Sinclair O'Brien · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Cedric Francois, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 8, 2016. Read the notice at the SEC .
equity SEC Dec 2014 $18 M No. 4 $10 to $50 million 1
Apellis Pharmaceuticals, Inc.: Raise no. 4, Dec 2014 × Investors in this round 1 investor had bought by the notice of Jun 9, 2015: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $18 M of $18 M offered
Smallest investment taken $10,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cedric Francois · Executive Officer, Director Pascal Deschatelets · Executive Officer A. Sinclair Dunlop · Director Alec Sinclair Machiels · Director Gerald Sinclair Chan · Director Stephanie Sinclair O'Brien · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Cedric Francois, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 9, 2015. Read the notice at the SEC .
equity SEC Jul 2013 $18 M No. 3 $10 to $50 million 25
Apellis Pharmaceuticals, Inc.: Raise no. 3, Jul 2013 × Investors in this round 25 investors had bought by the notice of Aug 27, 2014: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $18 M of $24 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cedric Francois · Executive Officer, Director Pascal Deschatelets · Executive Officer Alec Machiels · Director Gerald Chan · Director Stephanie O'Brien · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Pascal Deschatelets, Chief Operating Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 27, 2014. Read the notice at the SEC .
equity SEC May 2011 $3 M No. 2 $2 to $10 million 15
Apellis Pharmaceuticals, Inc.: Raise no. 2, May 2011 × Investors in this round 15 investors had bought by the notice of Jun 20, 2011: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken $20,000
What was sold equity
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cedric Francois · Executive Officer, Director Pascal Deschatelets · Executive Officer, Director Alec Machiels · Director David Darst · Director Douglas Onsi · Director Marie-Claude Bernal · Director Sinclair Dunlop · Director Stephen Gillies · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Pascal Deschatelets, Secretary/Director. Source: SEC Form D and 1 amendment, newest notice filed Jun 20, 2011. Read the notice at the SEC .
equity SEC May 2010 $2 M No. 1 Under $2 million 6
Apellis Pharmaceuticals, Inc.: Raise no. 1, May 2010 × Investors in this round 6 investors had bought by the notice of May 21, 2010: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $6 M offered; $4 M still to sell
Smallest investment taken $50,000
What was sold equity
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cedric Francois · Executive Officer, Director Pascal Deschatelets · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Pascal Deschatelets, Secretary/Director. Source: SEC Form D, newest notice filed May 21, 2010. Read the notice at the SEC .
equity SEC